Indication
RAD51 Gene Mutation
2 clinical trials
2 products
1 drug
Clinical trial
A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients With Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)Status: Active (not recruiting), Estimated PCD: 2024-07-30
Product
OlaparibClinical trial
Phase II Trial of PARP Inhibitor Niraparib for Men With High Risk Prostate Cancer and DNA Damage Response DefectsStatus: Recruiting, Estimated PCD: 2024-08-01
Drug
AtezolizumabProduct
Niraparib